This timeline, first appearing in AVAC Report 2014/15: HIV Prevention on the Line, shows PrEP going from proof-of-concept to prevention phenomenon in five years and can be used to anticipate and speed action on the next generation of ARV-based prevention options.
From Proof-of-Concept to Prevention Phenomenon in Five Years
HIV-Specific Neutralizing Antibodies: A guide to targets and candidates
A detailed graphic describing the status of pre-clinical and clinical work around relevant bNAbs today.
Where Does Oral PrEP Fit in to Vaccine and AMP Trials?
A global map showing current efficacy trial countries and their status of PrEP implementation.
Vaccine Approaches in Early-Phase Development
An outline of various approaches to vaccine development that are in earlier phase research, e.g., phase I or II trials; development pathways for these candidates are uncertain at this time.
Vaccines and Antibodies on Efficacy Pathways
A timeline of current efficacy programs for vaccines and antibodies, highlighting the P5 program testing pox-protein candidates, the Janssen program testing mosaic-based candidates, and the AMP studies testing the antibody VRC01.
MPT Product Development: Many possibilities for MPT development
This table shows the indication (prevention effect the product is designed to have—e.g., pregnancy or one or more STIs) the way it will be delivered (e.g., through vaginal gel, pill or injection), how it might work to provide preventive effect (for example, as a physical barrier to prevent fluid exchange or as a hormonal contraceptive) and what kind of dosage could be possible (e.g., daily pill or application, sustained through the blood or around sex).
Excerpted from the MPTs factsheet.
Evidence for HIV Prevention Options
What’s the big picture of ARV-based prevention trial results? This graphic shows the levels of efficacy from each major trial (the circles) with the confidence intervals around the finding (the bars at either side). Not sure what a confidence interval is? See our one-page Advocates’ Guide to Statistical Terms.
A Map of Missed Chances: Oral PrEP Rollout and Further Research on Dapvirine Vaginal Ring
Ideally, prevention strategies would be coordinated and integrated into comprehensive programs. The field would gain vital knowledge as people respond to a selection of options. Instead, product-specific programs, such as the delivery of oral PrEP or research trials on the dapivirine vaginal ring, become available in isolation from one another. Excerpted from AVAC Report 2016: Big Data, Real People.
Biomedical Prevention in 2016 – At a Glance
A snapshot of prevention strategies underway or under development from 2015-2020. Excerpted from AVAC Report 2016: Big Data, Real People.
Microbicides by the Numbers: Science, products, money and more
The term “microbicide” refers to substances being studied that could be used in the vagina and/or rectum to reduce the risk of HIV infection via sexual exposure. There are no licensed microbicides available today. Simple, easy-to-use microbicides would help these individuals take control of their own health—while offering people everywhere an additional, needed option. The graphics below represent key facts about the microbicide field.